Clinical implications of molecular heterogeneity in triple negative breast cancer.
Clinical implications of molecular heterogeneity in triple negative breast cancer.
复制标题
DOI：
10.1016/j.breast.2015.07.009
复制
发表时间：
2015-11
期刊：
影响因子：
--
通讯作者：
Pietenpol JA
中科院分区：
文献类型：
--
作者：
Lehmann BD;Pietenpol JA
三阴性乳腺癌(TNBC)是一种分子异质性疾病，缺乏复发的靶向性改变，因此治疗进展一直具有挑战性。由于缺乏ER、PR和HER2扩增，使得联合化疗成为辅助、新辅助和转移环境中的标准护理治疗选择。最近，多项研究揭示了TNBC的异质性，并确定了具有独特生物学特性的不同转录亚型。在这里，我们回顾了分子的异质性及其对先前和未来临床试验的影响。
Triple negative breast cancer (TNBC) is a molecularly heterogeneous disease lacking recurrent targetable alterations and thus therapeutic advances have been challenging. The absence of ER, PR and HER2 amplifications, leaves combination chemotherapy as the standard of care treatment option in the adjuvant, neoadjuvant and metastatic settings. Recently, multiple studies have shed some light on the heterogeneity of TNBC and identified distinct transcriptional subtypes with unique biologies. Herein we review the molecular heterogeneity and the impact on previous and future clinical trials.